I agree that this site is using cookies. You can find further informations here.
X
Gastinne, T.
52  results:
Search for persons X
?
1

AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐..:

Houot, R. ; Bachy, E. ; Cartron, G....
Hematological Oncology.  41 (2023)  S2 - p. 147-148 , 2023
Link: https://doi.org/10.1002/..
 
?
2

EARLY CTDNA CLEARANCE AFTER CAR T‐CELL INFUSION PREDICTS OU..:

Delfau‐Larue, M. ; Viailly, P. ; Cartron, G....
Hematological Oncology.  41 (2023)  S2 - p. 179-181 , 2023
Link: https://doi.org/10.1002/..
 
?
3

Transfusion needs after CD19 CAR T‐cells for large B‐cell l..:

Vic, S. ; Thibert, J. ; Bachy, E....
Hematological Oncology.  41 (2023)  S2 - p. 534-536 , 2023
Link: https://doi.org/10.1002/..
 
?
4

PROGNOSTIC SCORING SYSTEMS FOR SEVERE CRS AND ICANS AFTER A..:

Sesques, P. ; Di blasi, R. ; Legouill, S....
Hematological Oncology.  41 (2023)  S2 - p. 202-204 , 2023
Link: https://doi.org/10.1002/..
 
?
5

REALMA: Subset of patients with Marginal Zone Lymphomas fro..:

Bommier, C. ; Donzel, M. ; Rossi, C....
Hematological Oncology.  41 (2023)  S2 - p. 387-388 , 2023
Link: https://doi.org/10.1002/..
 
?
6

KILT: A RANDOMIZED NON‐COMPARATIVE PHASE II LYSA STUDY OF L..:

Cheminant, M. ; Carras, S. ; Bruneau, J....
Hematological Oncology.  41 (2023)  S2 - p. 838-839 , 2023
Link: https://doi.org/10.1002/..
 
?
7

Long term follow‐up of untreated/relapsing MCL patients wit..:

Le Gouill, S. ; Morschhauser, F. ; Chiron, D....
Hematological Oncology.  41 (2023)  S2 - p. 478-479 , 2023
Link: https://doi.org/10.1002/..
 
?
8

NATHALI‐01: A PHASE 1/2A TRIAL OF UCART20X22, AN ALLOGENEIC..:

Bachy, E. ; Ramakrishnan, A. ; Thieblemont, C....
Hematological Oncology.  41 (2023)  S2 - p. 825-826 , 2023
Link: https://doi.org/10.1002/..
 
?
9

S210: CAR T-CELLS ASSOCIATED ACUTE TOXICITY IN B-CELL NON-H..:

SESQUES, P. ; DI BLASI, R. ; LE GOUILL, S....
HemaSphere.  6 (2022)  - p. 111-112 , 2022
Link: https://doi.org/10.1097/..
 
?
10

P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT ..:

Cartron, G. ; Bachy, E. ; Tilly, H....
HemaSphere.  6 (2022)  - p. 1023-1024 , 2022
Link: https://doi.org/10.1097/..
 
?
11

S260: A MATCHED COMPARISON OF TISAGENLECLEUCEL AND AXICABTA..:

Bachy, E. ; Le Gouill, S. ; Sesques, P....
HemaSphere.  6 (2022)  - p. 161-162 , 2022
Link: https://doi.org/10.1097/..
 
?
12

Preliminary Clinical Data From Ongoing Phase 2 Study With E..:

Kindler, H. ; Harvey, R.D. ; Duska, L.R....
European Journal of Cancer.  174 (2022)  - p. S31-S32 , 2022
Link: https://doi.org/10.1016/..
 
?
13

LONG‐TERM FOLLOW‐UP AND BIOMARKER ANALYSES OF BRENTUXIMAB V..:

Driessen, J. ; Kersten, M. J. ; Visser, L....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
14

BRENTUXIMAB VEDOTIN AS CONSOLIDATION TREATMENT IN PATIENTS ..:

Gastinne, T. ; Bouabdallah, K. ; Moatti, H....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
15

AMAHRELIS : ADCETRIS MAINTENANCE AFTER AUTOLOGOUS STEM CELL..:

Marouf, A. ; Cottereau, A. S. ; Kanoun, S....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
1-15